Omega-3 (EPA + DHA)
Recovery · Polyunsaturated fatty acids
Tier A-
What this is
REDUCE-IT (2018) showed 25% CV event reduction with 4g icosapent ethyl in statin-treated high-risk patients, though STRENGTH (EPA+DHA) was negative — ongoing debate whether EPA alone vs mixed matters. 2024 meta-analyses show small signal for AF at high doses. Choose products with 3rd-party oxidation testing (TOTOX <10).
Mechanism
EPA/DHA incorporated into cell membrane phospholipids; compete with arachidonic acid; generate specialized pro-resolving mediators (resolvins, protectins, maresins); reduce pro-inflammatory eicosanoid production
Dose & route
1-4 g/day combined EPA+DHA; Rx icosapent ethyl 4 g/day
Citations
- https://pubmed.ncbi.nlm.nih.gov/30415628/
- https://pubmed.ncbi.nlm.nih.gov/33196766/
- https://pubmed.ncbi.nlm.nih.gov/34612033/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.